Evidence map›Paper›PMID 31741621›Full record

ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2019

Retrospective Analysis of Hairy Cell Leukemia Patients Treated with Different Modalities as First Line: Real-Life Experience Over 20 years.

Fergün Yılmaz, Dilan Atilla, Nagihan Akkaş, Hale Bülbül, Nur Soyer, Derya Demir, Demet Kiper, Aylin Avcı, Filiz Vural, Güray Saydam and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Fergün Yılmaz1Department of Hematology, Internal Medicine, Marmara University, Istanbul, Turkey.
Dilan Atilla2Department of Hematology, Internal Medicine, Ege University, Izmir, Turkey.
Nagihan Akkaş3İnternal Medicine, Department of Hematology, İzmir Katip Celebi University, Izmir, Turkey.
Hale Bülbül2Department of Hematology, Internal Medicine, Ege University, Izmir, Turkey.
Nur Soyer2Department of Hematology, Internal Medicine, Ege University, Izmir, Turkey.
Derya Demir4Department of Pathology, Ege University, Izmir, Turkey.
Demet Kiper3İnternal Medicine, Department of Hematology, İzmir Katip Celebi University, Izmir, Turkey.
Aylin Avcı5Department of Pathology, İzmir Katip Celebi University, Izmir, Turkey.
Filiz Vural2Department of Hematology, Internal Medicine, Ege University, Izmir, Turkey.
Güray Saydam2Department of Hematology, Internal Medicine, Ege University, Izmir, Turkey.
Fahri Şahin2Department of Hematology, Internal Medicine, Ege University, Izmir, Turkey.
Mine Hekimgil4Department of Pathology, Ege University, Izmir, Turkey.
Nazan Özsan4Department of Pathology, Ege University, Izmir, Turkey.
Raika Durusoy6Department of Public Heath, Ege University, Izmir, Turkey.
Bahriye Payzın3İnternal Medicine, Department of Hematology, İzmir Katip Celebi University, Izmir, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to analyze the characteristics and response rates of different treatment modalities in hairy cell leukemia patients over 20 diagnosed as hairy cell leukemia (HCL). Clinical data, response rates and survival outcome of the patients who were diagnosed with HCL were retrospectively analyzed. Fifty-two patients with a median age of 50 (28-87) years were enrolled in the study. 38 patients (73%) were male and male to female ratio was 2.7. First line therapy was cladrabine in 36 patients (69.2%). The overall response rate was 97%. CR and PR rates were 86.1% and 11.1%, respectively. Interferon was used in 10(19.2%) patients who were diagnosed before 2000s years. CR and PR rates were 70% and 30%, respectively. Although the CR rates were lower in IFN group, this difference could not be reached statistically significance (

Indexed as

CladrabinHairy cell leukemiaResponse ratesSurvival ratesTreatment

Identifiers

PMID31741621
PMCPMC6825084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.